A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)
A phase 3 trial of Vebreltinib run by Beijing Pearl Biotechnology Limited Liability Company in non-small-cell lung cancer and small-cell lung cancer, now recruiting.
Overview
A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2) is a phase 3 interventional study registered as NCT05989542 by Beijing Pearl Biotechnology Limited Liability Company, with 136 participants planned, started 2023-10-16. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Setting
An Open, Multi-center, Single-arm Phase IIIb Confirmatory Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Vebreltinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Exon 14 Mutation
Phase
Phase 3
Sponsor
Beijing Pearl Biotechnology Limited Liability Company
Registry
Enrolled
136
Similar pages
not linked directly; found by shared links- TrialVebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Shares Vebreltinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialVebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Shares Vebreltinib, Small-cell lung cancer, Non-small-cell lung cancer.